The Open Floor
Evidence-graded education, in plain language. Every claim carries a visible grade (Established, Emerging, or Anecdote) so you always know how much weight it holds. This bridges toward your clinician, never around them.
Best for. Something has changed and you can't explain it: weaker erections, less interest, a signal you don't know how to read.
You leave with. Why the change is worth a workup, and the full map of that workup before you book anything.
Start: Erectile function is a signal →Best for. A PDF full of numbers and reference ranges, and nobody has told you what any of it means.
You leave with. Enough fluency in testosterone, SHBG, insulin, and inflammation markers to hold a real conversation with your clinician.
Start: Read your labs →Best for. Choosing between the pills, daily versus on-demand, testosterone, or what comes next when pills stop working.
You leave with. The honest comparisons, the safety rules, and the dosing literacy to follow a prescription with your eyes open.
Start: The PDE5 line-up →Best for. A $400 quote on a $3 molecule, a subscription you can't unwind, or a stack of charges you can't parse.
You leave with. The cost stack unpacked, layer by layer, and the legal levers that bring the price down.
Start: What it costs →Best for. An erection that has lasted too long, a reaction that worries you, or a question that needs an answer tonight.
You leave with. The rescue ladder by the clock, what the ER actually does, and crisis resources one tap away.
Start: Support →The investigational AMPK and mitochondrial activator, formerly O304, has real early human data. The 2018 TELLUS study, the 23-person obesity trial, the 8% versus 'up to 33%' metabolism claims, minimal weight loss at the tested exposure, and why animal muscle-sparing results are not a human cutting protocol.
Often the first visible sign of a vascular or metabolic problem, years before a heart attack or a diabetes diagnosis. Why the body flags it here first, and why it's a reason to get a workup, not to feel shame.
An erection is a vascular event, and the vasculature adapts to training. The mechanism from intensity to blood flow, why vigorous intervals beat a gentle walk, where anaerobic work earns its place, and the heart-safety caveat that has to come first.
The most common sexual concern men raise, and one of the most treatable. The difference between lifelong and acquired PE, why it so often travels with erectile trouble, and the behavioral and medical options that actually work.
Sometimes the vasculature is intact and the erection still fails, because the nervous system overrides it. How the anxiety loop starts, why it feeds itself, how it blends with real blood-flow decline as you age, and what actually breaks it. Shaped with a contributor who lived it.
Curvature from a fibrous plaque, more common than men think, and not cancer. The two phases, why treatment timing is everything, and the injection, traction, and surgical options once it stabilizes.
Erectile dysfunction is a symptom, not a diagnosis. The full evaluation, from history and exam to the labs that find the cause, walked start to finish, so you know the map before you go, and know why skipping it is the part that costs you.
The oldest question in an ED workup: is the wiring intact? Nocturnal penile tumescence testing checks whether you get erections in your sleep, the classic way to separate a physical cause from a psychological one. What the home and clinic versions measure, why the answer is rarely black-and-white, and where it fits now.
The specialized test that measures your blood flow directly: what actually happens in the room, why the injection dose can make or break the result, when a contrast study (cavernosography) comes next, and the exact numbers (PSV, EDV, RI, both sides) to ask for so you can read the study instead of just hearing "it's fine."
When the Doppler suggests blood won't stay in but can't say exactly where it's escaping, this contrast study maps it. What dynamic infusion cavernosometry and cavernosography actually involve, why it's reserved for the few men considering surgery, and the honest limits of chasing a leak.
You got the workup. Now decode it. What total and free testosterone, SHBG, LH/FSH, fasting insulin, HbA1c, and hs-CRP actually mean, enough to have a real conversation with your clinician instead of guessing.
Most of the difference between safe TRT and the gray zone is a real diagnosis and real monitoring. What it is and isn't, the labs that keep it safe, how to make it affordable through legitimate coverage and cash levers, and the hard line between replacement and anabolic enhancement.
When they seem to stop working, the drug usually hasn't worn out: your vasculature has changed. The emerging case for long-term vascular benefit, and why your blood-pressure drug choice (nebivolol, telmisartan) matters when you have both ED and hypertension.
Viagra vs Cialis vs the rest, answered. How the four PDE5 inhibitors compare on speed, duration, food, and on-demand vs daily, plus the one hard safety rule they all share, and why they're more alike than different.
The fear is that testosterone therapy makes you infertile, full stop. The reality is calmer: TRT suppresses sperm while you're on it, but for most men it's a non-issue, usually reversible, often preventable, and only a real concern if you're actively trying to conceive.
The first ED treatment that claims to repair rather than assist. The Israeli trials that started it, the meta-analyses (a few IIEF points, mostly in mild vascular ED), how long it lasts, why guidelines still call it investigational, the focused-versus-radial device problem behind most clinic offerings, and the honest case for who should consider it.
Nerve-sparing surgery stuns the erection nerves for a year or more, and tissue that never fills starts to scar. What the rehabilitation trials really showed about daily tadalafil, vacuum devices, and injections; a deep dive into pelvic floor muscle training, the one intervention that helps continence, climacturia, and erections at once; and the emerging frontier from NeuroSAFE to stem cells.
The only FDA-approved drug for Peyronie's disease is a bacterial enzyme injected straight into the scar. What the IMPRESS trials measured (about 17 degrees, not a straight line), the eight-injection course and the modeling that goes with it, the 30 to 90 degree window, the corporal-rupture risk, the sex-embargo weeks, and why the same vial treats a bent finger.
When PDE5 pills fail or can't be used, there's a real, effective second line, and the most reliable of it is trimix, injected. What it is, where it sits on the treatment ladder, how the dose actually gets set, numbers included, and the one rule that isn't optional: the four-hour priapism emergency.
A molecule that failed the ED market on its own evidence in 2001 is back inside "3-in-1" sublingual troches from compounding pharmacies and telehealth brands. What apomorphine actually does, why Uprima died, which ingredient in the troche is doing the work, and why the locker-room conversation quietly moved to androgens instead.
One works on desire in the brain, the other on the erection itself, so combining them has real pharmacological logic, and early trials helped PDE5 non-responders. But bremelanotide raises blood pressure, it's off-label in men, and most of what's sold isn't the approved drug. The honest picture.
The specialist visit is where the workup gets real, and where too many men go passive. How to prepare for the appointment, and for the Doppler if one's coming, why precision about what you already take protects your diagnosis, the data to leave with, and how to push back when the visit turns into a conveyor belt. Shaped with a contributor who learned it the expensive way.
Telemedicine can deliver real men's-health care, or a checkout form with a doctor's signature stapled on. The difference is whether anyone actually evaluated you. The green flags, the pill-mill red flags, and the questions to ask.
The price is a stack: labs, a consult, the product, and the markup on top. Follow the journey layer by layer, see where the prescriber's cut hides, and learn how to get the most value inside the legal channel in your jurisdiction.
The molecule went generic years ago. The gap between $3 and $400 is markup, not medicine. Transparent-pricing pharmacies like Cost Plus Drugs, the 90-day lever, and why a higher strength can cost less per dose, which is a prescriber conversation and not a DIY recipe.
Pumps, fillers, traction, surgery, jelqing, peptide healing stacks, growth hormone, and the gray-market injections that maim: the enhancement landscape mapped and graded, method by method. What legitimately helps, what's only temporary, and what to never let near you.
Lyophilized vial, pre-mixed solution, or a ziplock of premix? How the form of an injectable peptide or ED medication reveals where it came from, and whether anyone licensed stood behind its quality.
Trapped blood turns acidotic within hours, smooth muscle starts dying by around hour twelve, and by hour thirty-six the odds of recovering an erection are grim. The ischemic priapism damage timeline from the AUA/SMSNA guideline, hour by hour, and what each hour means for the fix.
Tadalafil for the gym pump is a real trend with real pharmacology behind it: PDE5 lives in your muscles' blood vessels too. But the performance trials mostly say it does nothing, one shows raised muscle-damage markers, and the blood-pressure math with pre-workout stacks is worse than the pump is worth.
The internet's rudest search term describes something sexual medicine takes seriously: men who climax easily solo but can't finish with a partner, often because their technique trained them that way. What the evidence actually says, what it doesn't, and the retraining that works.
Constriction rings are supposed to come off after 30 minutes. When one won't, it's the same ischemic clock as priapism, wound around the outside: swelling tightens the trap, the injury grades climb with the hours, and the only variable that decides the outcome is how long you wait. The warning signs and what the ER actually does.
The study behind the famous 7-day testosterone spike was retracted in 2021, the spike was never replicated, and even at face value it describes a blip, not a superpower. What the semen-retention evidence actually says, including the prostate-cancer finding that points the other way.
The viral honey-packet trend, sold at gas stations and on TikTok, is honey plus hidden prescription drugs. FDA lab testing found sildenafil and tadalafil in dozens of named products, at unknown doses. What's actually in the packet, the documented injuries, and how to read the risk.
Erythrocytosis is the most common TRT side effect, and the advice that follows it is a mess: the guideline's 54% number versus the borrowed 45%, the misread blood-donation studies, the altitude and athlete myths, the delivery-route and BP-drug levers that actually move it, and the ferritin crash from repeated phlebotomy that nobody tests for.
Most patients withhold something from a clinician, and men in an erectile dysfunction workup withhold the things that matter most: the real drug list, steroid history, poppers, the supplement bag, how often it actually fails. The nondisclosure literature on why, and the concrete cost of each omission (a mis-dosed Doppler, a hidden nitrate interaction, a missed hypogonadism, a wrong psychogenic label), ending with what to actually say.
Uprima, yohimbine, Vasomax, papaverine, Topiglan and Vitaros, the nasal apomorphine that never launched, Enzyte, ExtenZe, and the gas-station Rhino wave: what each was, why it sold, why it was pulled, and what we learned. Ranked against a printed rubric (evidence at launch, harm, honesty of marketing). The closing lesson is that PDE5 inhibitors, alprostadil, and implants are still here because trials and regulators did their job.
Mesterolone (Proviron) is a real 1960s Schering androgen, oral, non-aromatizing, weakly anabolic, a strong SHBG binder. Its two approved-era indications tested weak or null, no trial has ever tested it for erectile function, and the closest controlled evidence for its class (DHT gel trials) shows at most a transient effect in androgen-deficient men. Schedule III in the US with no legal channel. The honest version of the signal is a lab draw with a clinician, not a package.
A Croatian gastric-peptide lab, a racehorse-doping fragment, and a bodybuilding forum produced the internet's favorite "healing stack." The rodent data is real and broad; controlled human evidence is essentially absent, no dose was ever established, WADA and USADA prohibit both, and the FDA compounding saga left the only supply gray-market. Why it shows up after enhancement injuries and next to trimix, and why the smart move is the conversation the forums always dodged.
Thunder's Place, MattersOfSize, PEGym, then Reddit: the vocabulary, the measuring rituals, the gains logs, the earned reputation, and the survivorship bias that wrote the FAQ. Set against the evidence: small-effect traction trials, no trials and a documented injury record for manual methods, and clinic data showing the men seeking enlargement were almost all already normal.